NEW YORK, Dec. 30, 2016 -- Mr. Charles Wade Dummer has been selected to join the Industry Board at the American Health Council. He will be sharing his knowledge and expertise on data analysis and visualization, biomedical engineering, patient risk management, process validation, and design control.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/2847216e-2977-491b-87d8-c3a4600e33da
With eighteen years of experience in the field, Mr. Dummer excels in his role as the Senior Manager of Technical Services and Risk Management at Fresenius Medical Care. Based in Layton, Utah, Fresenius Medical Care North America (FMCNA) is the world’s only fully vertically integrated renal company that provides the highest quality care for individuals with renal and other chronic conditions. As the country’s largest practice of hospitalist and post-acute providers, FMCNA has the most comprehensive line of dialysis equipment, disposable products, and renal pharmaceuticals.
Since joining the Fresenius Medical Care North America Quality team in 2012, Mr. Dummer’s day-to-day responsibilities include the management of the Technical Service Department (Patient-Centered Risk Management, Metrology, Precision Measurement, Process Validation, and Statistical Services), and oversight of the validation process and risk management of products. Mr. Dummer became interested in the biomedical engineering field when he desired to help a family member that suffered from the rare Polycystic Kidney Disease.
In 2000, Mr. Dummer earned his Master’s in Biomedical Engineering from the University of Utah. Prior to that, in 1996, he received his Bachelor of Science in Molecular Biology from the Brigham Young University.
Mr. Dummer was instrumental in the establishment of the Technical Service Department at the FMC Ogden Facility, revamped the Patient Risk Management System at the FMC Ogden Facility, and co-invented patents for a molecular diagnostic device and a non-invasive urea monitoring system for use during hemodialysis.
Mr. Dummer maintains affiliations with the following organizations: American Society of Quality (ASQ), and Parenteral Drug Association (PDA). He attributes his success to his drive to learn, applying engineering problem-solving principles in all applications, and the way that he approaches a problem creatively. Additionally, he is proud of the support from his family including his lovely wife Shanna and their children Adam, Liza, Makenna, and Maggie.
Looking ahead, Mr. Dummer hopes to establish a fully QS-Integrated Risk Management system (from key process outputs to product failure-modes to patient harm rates) to provide real-time risk-based decisions; to establish semi-automate critical statistical analyzes to minimize misuse of statistical methods in process validation and risk management; and, to continue to focus on building the individuals he works with to be independent, critical thinkers, and well-balanced individuals who enjoy the satisfaction of meaningful contribution.
In his free time, Mr. Dummer enjoys music, singing, playing piano and guitar, theater, gardening, water and snow skiing, soccer, hiking with his family, and writing stories for young children.
For more information, please contact: Elizabeth Moore American Health Council Hauppauge, NY United States Phone: 1-212-390-0214 Email: [email protected]


Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
OpenAI Explores Massive Funding Round at $750 Billion Valuation
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



